Serum antibody responses to toxic shock syndrome (TSS) toxin 1 (TSST-1) and staphylococcal enterotoxins A, B, and C were determined by Western blot (immunoblot) analysis of acute-and convalescent-phase paired sera from 18 TSS-and 31 non-TSS-associated Staphylococcus aureus infections. Compared with non-TSS cases, seroconversion to TSST-1 was significantly more frequent among both menstrual (5 of 8 versus 1 of 31; P < 0.001) and nonmenstrual (3 of 10; P < 0.05) patients. Seroconversion to staphylococcal enterotoxm A was also more frequent among both menstrual (2 of 8 versus 0 of 31; P < 0.05) and nonmenstrual (2 of 9; P < 0.05) TSS patients. In general, patients with TSS associated with TSST-1-positive S. aureus were more likely to seroconvert exclusively to TSST-1 (4 of 12 versus 0 of 6; P = 0.16), whereas those associated with TSST-1-negative S. aureus were more likely to seroconvert exclusively to enterotoxins (3 of 6 versus 0 of 11; P < 0.05). Concurrent seroconversions to multiple exoproteins were more frequent among both menstrual (3 of 8; P < 0.05) and nonmenstrual (2 of 9; P < 0.05) TSS patients compared with persons without TSS (0 of 31). These data suggest but do not prove that enterotoxins (especially staphylococcal enterotoxin A) in addition to TSST-1 may be involved in both menstrual and nonmenstrual TSS. Furthermore, since exposure to multiple exoproteins is more likely to occur during TSS-associated than non-TSS-associated S. aureus infections, the possibility of additive or synergistic effects of these putative toxins in the pathogenesis of TSS should be further explored.
Toxic shock syndrome (TSS) associated with menstruation and tampon use (menstrual TSS) is believed to be mediated by a staphylococcal exoprotein, TSS toxin 1 (TSST-1) (1, 15) . More recently, cases of TSS in men and in women not associated with menstruation are increasingly recognized (7, 12) . Nonmenstrual TSS is usually associated with focal Staphylococcus aureus wound or soft tissue infections. Whereas vaginal S. aureus isolates associated with menstrual TSS usually produce TSST-1 when tested in vitro (85 to 100% of strains), nonmenstrual TSS isolates are less often positive (only 62 to 76% of strains) (7, 14) . Nonmenstrual and menstrual TSS isolates also differ phenotypically in other characteristics (4), suggesting different origins or pathogenesis in these two variants of TSS. Recently, Crass and Bergdoll (5) reported that 60% of TSSassociated S. aureus also produced staphylococcal enterotoxin A, B, or C (SEA, SEB, or SEC, respectively) and that acute-phase sera from patients with TSS had lower levels of antibody to these enterotoxins than did healthy controls. Previous studies, however, had not compared TSS-associated with non-TSS-associated S. aureus infections, and paired sera (acute and convalescent phases) were The presence of immunoglobulin G antibodies to TSST-1, were incubated at room temperature for 2 h on a rotating SEA, SEB, and SEC in the acute-phase sera from 8 menplatform, washed with Tris-buffered saline containing 0.5% strual TSS, 10 nonmenstrual TSS, and 31 non-TSS patients Tween 20 and 0.5% bovine serum albumin, and incubated for was first examined ( Table 2) . TSST-1-specific immunoglob-30 min with streptavidin-horseradish peroxidase (BRL Life ulin G in acute-phase sera was more frequently absent from Technologies). Immunoreactive bands were visualized with menstrual TSS patients than from non-TSS controls (6 of 8 4-chloronaphthol substrate (BRL Life Technologies). Rabbit versus 3 of 31; P < 0.001). Nonmenstrual TSS patients (3 of antisera with monospecific activity against TSST-1, SEA, 10) were not significantly different from non-TSS controls. SEB, SEC1, SEC2, and SEC3 (Toxin Technology Inc.) and
Rates of antibodies to SEA, SEB, and SEC among these pooled normal human serum were used in similar immunopatient groups were not significantly different. Patients who blots to positively identify the exoprotein antigens and to had negative antibodies in acute-phase sera but subsequently assess cross-contamination or cross-reactivity of the exoprodeveloped positive antibodies in paired convalescent-phase tein preparations. Preliminary studies by Coomassie and sera were then separately analyzed (Table 2 ; Fig. 1 and 2 ). silver staining after sodium dodecyl sulfate-polyacrylamide Compared with non-TSS cases, seroconversion to TSST-1 gel electrophoresis and by immunoblots with rabbit monowas significantly more frequent among both menstrual TSS specific antiserum or pooled normal human serum demon-(62 versus 3%; P < 0.001) and nonmenstrual TSS (30%; P < strated excellent purity of the exoprotein preparations and 0.05) patients. Interestingly, seroconversion to SEA was absence of cross-contamination or cross-reactivity, except also more frequent for both menstrual TSS (25 versus 0%; P among SEC1, SEC2, and SEC3 when immunoblotted with < 0.05) and nonmenstrual TSS (22%; P < 0.05) patients. pooled normal human serum, as expected. In nonreducing Seroconversion to SEB occurred in only one instance in a gels (without mercaptoethanol), the apparent molecular size menstrual TSS patient who also seroconverted to TSST-1 of TSST-1 was 24 kilodaltons, and those of SEA, SEB, and SEA (Fig. 1 ). The seroconversion rates to SEC were 14.w5-C 4 : : r-FIG. 1. Western blot analysis of acute-and convalescent-phase sera from a menstrual TSS patient. Partially purified TSST-1, SEA, SEB, and SEC were electrophoretically transferred to nitrocellulose and probed with paired acute-phase (A) or convalescent-phase (C) sera. MW, Molecular weight standards. This patient clearly demonstrated an absence of immunoglobulin G against TSST-1, SEA, and SEB in her acute-phase serum and subsequent multiple seroconversions to these exoproteins in her convalescent-phase serum. similar in all three patient groups. The relationship of TSST-1-positive S. aureus and seroconversion to TSST-1 and enterotoxins was further examined (Table 3) . Among the eight menstrual TSS cases, all of which were associated with TSST-1-positive S. aureus, five (62%) seroconverted to TSST-1; two (25%) seroconverted exclusively to TSST-1, whereas none seroconverted exclusively to enterotoxins. Among the 10 nonmenstrual TSS patients, only 4 were associated with TSST-1-positive S. aureus; of these, 2 (50%) seroconverted exclusively to TSST-1 and none seroconverted exclusively to enterotoxins. In contrast, among the six nonmenstrual TSS cases associated with TSST-1-negative S. aureus, three (50%) seroconverted exclusively to enterotoxins, whereas none seroconverted to TSST-1. Thus, TSS patients associated with TSST-1-positive S. aureus were more likely to seroconvert exclusively to TSST-1 (4 of 12 versus 0 of 6; P = 0.16), whereas TSS patients associated with TSST-1-negative S. aureus were more likely to seroconvert exclusively to enterotoxins (3 of 6 versus 0 of 9; P < 0.05). Concurrent seroconversion to multiple exoproteins ( Fig. 1) was more frequent among both menstrual TSS (3 of 8; P < 0.01) and nonmenstrual TSS (2 of 9; P < 0.05) patients compared with non-TSS-associated controls (0 of 31). serologic data by enzyme-linked immunosorbent assay (13) and those of Stolz et al. (17) and others (2, 3) . These data lend further support to the etiologic role of TSST-1 in the pathogenesis of both menstrual and nonmenstrual TSS. Furthermore, since seroconversion rates to SEA were also significantly higher among both menstrual and nonmenstrual TSS patients compared with non-TSS-associated controls, this staphylococcal enterotoxin may also be implicated in some cases of TSS. Crass and Bergdoll (6) observed that although TSST-1 was the major exoprotein produced in TSS-associated S. aureus (over 90% of strains), enterotoxins (SEA and SEC) were also produced in over 60% of these isolates. Among 55 S. aureus isolates associated with nonmenstrual TSS, only 12 (22%) produced TSST-1 alone, whereas 34 (62%) produced SEA or SEC in addition to TSST-1, 8 (14%) produced SEB alone, and 1 produced neither TSST-1 nor enterotoxins. Schlievert (14) reported that SEB was significantly correlated with TSST-1-negative TSS-associated S. aureus compared with non-TSS-associated control isolates. Garbe et al. (7) and Scott et al. (16) provided evidence that TSST-1-negative strains of S. aureus associated with nonmenstrual TSS produced illness and death in the rabbit similarly to TSST-1-positive strains. Parsonnet et al. (10) found that TSST-1-negative TSS-associated S. aureus frequently produced enterotoxins in vitro, primarily SEA and SEB, and that such strains were found to be significantly more potent inducers of interleukin-1 in human monocytes, compared with TSST-1-negative non-TSS-associated control strains. These investigators further reported that purified SEA was more potent than TSST-1 in inducing interleukin-1 and causing lethality in the rabbit by constant subcutaneous infusion (8, 11) . They postulated that induction of interleukin-1 or tumor necrosis factor by TSST-1 and enterotoxins may provide a common pathway by which staphylococcal products from both TSST-1-positive and -negative S. aureus might cause TSS. Our finding that menstrual and nonmenstrual TSS patients associated with TSST-1-positive S. aureus were more likely to seroconvert exclusively to TSST-1, whereas nonmenstrual TSS patients with TSST-1-negative S. aureus were more likely to seroconvert exclusively to enterotoxins, is consistent with this hypothesis. Although 7 of our 18 (39%) TSS patients failed to seroconvert either to TSST-1, SEA, SEB, or SEC, this does not necessarily imply that these patients were not exposed to these exotoxins. We and others have previously demonstrated that TSS patients may have a deficient antibody response and that this postulated deficiency could explain the high risk for recurrence in some TSS patients (2, 5, 13, 17) . However, such occurrence must be rare, since only one of our nine patients who lacked TSST-1 antibody in their acute-phase sera and were infected with TSST-1-producing S. aureus failed to seroconvert during convalescence. Conversely, demonstration of specific antibody by the very sensitive Western blot technique does not necessarily indicate the existence of protective titers to the exoproteins in question. The seroconversions confirmed by Western blot in our patients, however, should suggest the minimum rate of exposure to these exoproteins during either TSS-associated or non-TSS-associated S. aureus infection. It is also of interest that concurrent seroconversions to multiple exoproteins were significantly more frequent during TSS-associated than non-TSS-associated illness. This raises the possibility that these toxins could interact additively or synergistically in vivo in producing the clinical manifestations of TSS. Crass and Bergdoll (5) noted that TSS-associated isolates producing both SEC and TSST-1 were associated with a higher case fatality rate than was any other toxin combination. Interactions of different staphylococcal toxins in vivo may also explain the variable spectrum of clinical illness in human disease and in animal models of TSS. The role of these exoproteins and their possible interactions in the pathogenesis of TSS should be further explored.
